Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DBI-002 in tinea versicolor
NCT04937920Phase 2Completed
- Sponsor
- DermBiont, Inc.
- Start
- Mar 2021
- Primary completion
- Sep 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DBI-002 probiotic gel in tinea versicolor (3 arms), sponsored by DermBiont, Inc. Primary endpoint: Molecular Diagnostic qPCR Comparison of DBI-002 Drug Product and Malassezia at 14 days. Started Mar 2021; status: completed.
02
Drugs
DBI-002 probiotic gel
03
Conditions
tinea versicolor
Beyond the preview
Go deeper on NCT04937920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04937920.